BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Cyclin dependent kinase 7 (CDK7)

November 5, 2015 8:00 AM UTC

In vitro and mouse studies suggest inhibiting CDK7 could help treat triple-negative breast cancer (TNBC). In multiple human TNBC cell lines, the CDK7 inhibitor THZ1 decreased proliferation and expression of CDK7 target genes compared with vehicle. In an orthotopic mouse model and two patient-derived xenograft models of TNBC, a THZ1 analog decreased tumor growth compared with vehicle. Next steps include testing THZ1 in TNBC patients...